FDA Approves an Autoinjector Version of LEROCHOL® (lerodalcibep-liga) and Updated Indication

FDA also approved a positive update to the LEROCHOL indication statement reflecting the well-recognized reduction of risk for major adverse cardiovascular events achieved in adults via LDL-C lowering when treated with statins or with monoclonal antibody PCSK9 inhibitors used as an add-on to statin therapy